Abstract: This invention relates to certain 6-aryl-7-halo-imidazo[1,2-a]pyrimidines or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals by promotion of microtubule polymerization. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof.
Abstract: Mutant cholera holotoxins comprising a cholera toxin subunit A having single amino acid substitutions in the amino acid positions 16 or 72 or a double amino acid substitution in the amino acid positions 16 and 68 or 68 and 72 have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in immunogenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.
Type:
Grant
Filed:
June 5, 2002
Date of Patent:
October 23, 2007
Assignees:
Wyeth Holdings Corporation, The Regents of the University of Colorado, A Body Corporate
Inventors:
Bruce A. Green, Randall K. Holmes, Michael G. Jobling, Duzhang Zhu
Abstract: Compounds of the formula are useful in treating disease conditions mediated by TNF-?, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease and HIV.
Type:
Grant
Filed:
November 1, 2002
Date of Patent:
October 16, 2007
Assignee:
Wyeth Holdings Corporation
Inventors:
Vincent Premaratna Sandanayaka, Efren Guillermo Delos Santos
Abstract: The present invention relates to novel, low molecular weight broad spectrum compounds in particular to a class of 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid or their derivatives which have ?-lactamase inhibitory and antibacterial properties. The compounds are therefore useful in the treatment of antibacterial infections in humans or animals, either alone or in combination with other antibiotics.
Abstract: There is provided a process for the preparation of bicyclicheteroaryl carboxaldehydes having the structural Formula I where X and Y are defined in the specification The bicyclic heteroaryl carboxaldehydes are useful as intermediates in the preparation of ?-lactamase inhibitors.
Type:
Grant
Filed:
May 12, 2004
Date of Patent:
October 2, 2007
Assignee:
Wyeth Holdings Corporation
Inventors:
Michael William Winkley, Anita Wai-Yin Chan, Ivo L. Jirkovsky, Kenneth Alfred Martin Kremer, Joseph Zeldis, Antonia Aristotelevna Nikitenko, Henry Lee Strong, Tarek Mansour, Gulnaz Khafizova, Aranapakam M. Venkatesan
Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-?, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.
Abstract: Outer-membrane vesicles, Class 1 outer membrane proteins of Neisseria meningitidis, fragments or oligopeptides containing epitopes of the Class I OMP can be used to immunize against meningococcal disease.
Type:
Grant
Filed:
June 5, 1995
Date of Patent:
July 3, 2007
Assignee:
Wyeth Holdings Corporation
Inventors:
Robert C. Seid, Jr., Peter R. Paradiso, Jan T. Poolman, Peter Hoogerhout, Emmanuel J. H. J. Wiertz, Peter van der Ley, John Edward Heckels, Ian Nicholas Clarke
Abstract: Immunogenic polysaccharide-protein conjugates having a polysaccharide antigen (or its oligosaccharide fragment representing one or more antigenic epitopes) derived from a nosocomial pathogen conjugated to a staphylococcal surface adhesin carrier protein are used in immunogenic compositions to elicit antibody responses to both the polysaccharide antigen and the staphylococcal surface adhesin carrier protein. Such immunogenic compositions are used to immunize against diseases caused by Staphylococcal aureus, Staphylococcal epidermidis or other nosocomial pathogens.
Type:
Application
Filed:
November 7, 2006
Publication date:
June 21, 2007
Applicants:
Wyeth Holdings Corporation, Inhibitex, Inc.
Inventors:
Viliam Pavliak, Steven Baker, Subramonia Pillai, Joseph Patti, Bradley Prater
Abstract: The present invention relates to novel, low molecular weight broad spectrum compounds in particular to a class of 4-substituted or unsubstituted-7-hydro-1,4-thiazepine-7-[bicyclic or tricyclic heteroaryl] substituted-3,6-dicarboxylic acid or their derivatives which have ?-lactamase inhibitory and antibacterial properties. The compounds are therefore useful in the treatment of antibacterial infections in humans or animals, either alone or in combination with other antibiotics.
Abstract: Self-propagating, fusogenic blebs are produced from cells infected with a population of Venezuelan Equine Encephalitis virus replicon particles (VRP). The self-propagating, fusogenic nature of the blebs is derived from expression of heterologous genes encoding viral fusion proteins that are incorporated into the replication defective replicon particles. The resulting blebs can be harvested from supernatants of cells displaying severe cytopathic effects. The blebs are used to make immunogenic compositions and devise methods of immunizing mammals against paramyxoviruses such as parainfluenza virus type 3.
Abstract: Mutant cholera holotoxins having single or double amino acid substitutions or insertions have reduced toxicity compared to the wild-type cholera holotoxin. The mutant cholera holotoxins are useful as adjuvants in antigenic compositions to enhance the immune response in a vertebrate host to a selected antigen from a pathogenic bacterium, virus, fungus, or parasite, a cancer cell, a tumor cell, an allergen, or a self-molecule.
Type:
Application
Filed:
December 22, 2006
Publication date:
May 31, 2007
Applicants:
Wyeth Holdings Corporation, University of Health Sciences
Inventors:
Bruce Green, Randall Holmes, Michael Jobling, Duzhang Zhu
Abstract: The present invention provides immunogenic and pharmaceutical compositions for the treatment and prevention of human papillomavirus (HPV)-associated cancers and in particular, cervical cancer. In particular, this invention relates to fusion proteins, and the nucleic acids encoding these fusion proteins, used to generate immune responses against HPV. Specifically, this invention provides for fusions of HPV E6 and E7 in which the E6 and/or E7 contains one or more mutations. These mutations abrogate the transformation activity of these oncogenic proteins and, thus, confer safety to the E6/E7 fusions. In addition, these fusions maintain or increase the immunogenic efficacy of E6 and E7. Any gene or protein delivery method can be used to deliver or package the immunogenic compositions of the present invention.
Type:
Grant
Filed:
October 2, 2003
Date of Patent:
May 29, 2007
Assignee:
Wyeth Holdings Corporation
Inventors:
Maria Cristina Cassetti, Larry Smith, Jeffrey K. Pullen, Susan P. McElhiney
Abstract: The present invention provides a purified preparation containing a polynucleic acid encoding at least one polypeptide selected from the group consisting of proteins encoded by one or more open reading frames (ORF's) of an Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), proteins at least 80% but less than 100% homologous with those encoded by one or more of ORF 2, ORF 3, ORF 4 and ORF 5 of an Iowa strain of PRRSV, proteins at least 97% but less than 100% homologous with proteins encoded by one or both of ORF 6 and ORF 7 of an Iowa strain of PRRSV, antigenic regions of such proteins which are at least 5 amino acids in length and which effectively stimulate immunological protection in a porcine host against a subsequent challenge with a PRRSV isolate, and combinations thereof, in which amino acids non-essential for antigenicity may be conservatively substituted.
Type:
Grant
Filed:
March 19, 2001
Date of Patent:
May 29, 2007
Assignees:
Wyeth Holdings Corporation, Iowa State University Research Foundation, Inc.
Inventors:
Prem S. Paul, Xiang-Jin Meng, Patrick Halbur, Igor Morozov, Melissa A. Lum
Abstract: This Invention provides a compound of the Formula: wherein X is R1, R2, R3 and R4 are described in the specification and a pharmaceutical composition comprising the compound used for inhibiting replication of a herpes virus.
Abstract: The present invention is concerned with isolated infectious bursitis (or bursal) disease virus(es) and a vaccine containing said virus(es) which is capable of protecting poultry against disease caused by infectious bursitis virus, characterized in that the vaccine virus(es) has/have the combined properties of, upon administration to a chicken, causing a reduction in the bursal size, expressed as bursa/body weight ratio, of less than 55%, and the capability to protect poultry having an ELISA antibody titer of at least about 500.
Type:
Grant
Filed:
January 29, 1998
Date of Patent:
May 1, 2007
Assignee:
Wyeth Holdings Corporation
Inventors:
Frans Gerrit Davelaar, Bernarda Johanna Pitstra, Nico Van Wiltenburg
Abstract: This invention relates to a new antibiotic designated P175-A, to production of fermentation of Micromonospora echinospora NRRL 30633, to methods for recovery and concentration from the crude solutions, and to a process for purification and to semisynthetic esters and ethers of P175-A.
Type:
Grant
Filed:
April 28, 2004
Date of Patent:
May 1, 2007
Assignee:
Wyeth Holdings Corporation
Inventors:
Haiyin He, Hui Yu Yang, Scott William Luckman, Valerie S. Bernan
Abstract: Hydroxamic acids having the formula are useful in treating disease conditions mediated by TNF-?, such as rheumatoid arthritis, graft rejection, cachexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease or HIV infection.
Abstract: The invention provides new substantially pure antibiotics designated AC-98-1, AC-98-2, AC-98-3, AC-98-4 and AC-98-5 derived from the microorganism Streptomyces hygroscopicus.
Abstract: The use of an aminoalkyl glucosamine phosphate compound, or a derivative or analog thereof, in combination with a cytokine or lymphokine such as granulocyte macrophage colony stimulating factor or interleukin-12, is useful as an adjuvant combination in an antigenic composition to enhance the immune response in a vertebrate host to a selected antigen.
Abstract: The invention relates to a new antibiotic designated Cyan426-A, to its production by fermentation, to methods for its recovery and concentration from the crude solutions, and to a process for its purification and to semisynthetic ethers of Cyan426-A, Cyan426-A-ethers.